Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It has been studied for its effects on pituitary growth hormone signalling, IGF-1 responses and visceral adipose tissue. The visceral-fat findings come from clinical studies involving people with HIV-associated abdominal fat accumulation.
Commonly researched areas of interest
GHRH receptor signalling
Growth hormone and IGF-1 responses
Visceral adipose tissue in clinical studies
Body composition and metabolic markers
Relationships between hormone responses and adipose tissue changes
Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH). Research has examined its effects on growth hormone and IGF-1 responses, as well as visceral adipose tissue in clinical studies involving adults with HIV-associated abdominal fat accumulation.
For research use
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It has been studied for its effects on pituitary growth hormone signalling, IGF-1 responses and visceral adipose tissue. The visceral-fat findings come from clinical studies involving people with HIV-associated abdominal fat accumulation.
Commonly researched areas of interest
GHRH receptor signalling
Growth hormone and IGF-1 responses
Visceral adipose tissue in clinical studies
Body composition and metabolic markers
Relationships between hormone responses and adipose tissue changes
Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH). Research has examined its effects on growth hormone and IGF-1 responses, as well as visceral adipose tissue in clinical studies involving adults with HIV-associated abdominal fat accumulation.
For research use